In a systematic review and meta-analysis of trials of non-vitamin K oral anticoagulants vs. single antiplatelet therapy, ...
A systematic review and meta-analysis estimating the differences in bleeding risks between therapeutic-dose non-vitamin K oral anticoagulants (NOACs) and single antiplatelet therapy (aspirin) found ...
A systematic review and meta-analysis of nine trials comparing non-vitamin K oral anticoagulants with low-dose aspirin revealed a link between rivaroxaban and higher rates of major bleeding and ...
The OCEANIC-AF trial has raised concerns about factor XI inhibitors. Should physicians still bet on this class of ...
Medicare changes will cut $1 billion from 2025 revenue, with Pfizer now responsible for 20% of catastrophic drug costs. Read ...
Rates of major bleeding and intracranial hemorrhage are similar for apixaban and dabigatran versus aspirin, while rates are ...
Background Anticoagulation therapy reduces stroke risk in patients with atrial fibrillation (AF), but it is often underused ...
LOS ANGELES -- In the PRESTIGE-AF trial, survivors of intracerebral hemorrhage (ICH) had good protection against future ischemic events using direct oral anticoagulants (DOACs) -- though, as feared, ...
for stroke prevention in low-risk patients (CHA2DS2-VASc score of 0–1). Novel anticoagulants include dabigatran, rivaroxaban and apixaban. Based on the RE-LY study, a 150-mg dose of dabigatran ...
Opdualag – a fixed-dose combination of LAG-3 inhibitor relatlimab ... shares in first-line metastatic melanoma are in the low double digits for Opdualag," with some use of the drug also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback